Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singulair Switch Among Merck's OTC Possibilities

This article was originally published in The Tan Sheet

Executive Summary

Merck may seek an OTC switch of its best-selling Singulair prescription medication, most likely asking for a nonprescription indication for allergic rhinitis

You may also be interested in...



Sanofi’s Nasacort AQ Rx-To-OTC Switch Under FDA Review

FDA’s Nonprescription Drugs Advisory Committee will meet July 31 to discuss Sanofi’s application to switch the intranasal corticosteroid Nasacort AQ to OTC sale, to be indicated for relief of hay fever symptoms in adults and children.

Sanofi’s Nasacort AQ Rx-To-OTC Switch Under FDA Review

FDA’s Nonprescription Drugs Advisory Committee will meet July 31 to discuss Sanofi’s application to switch the intranasal corticosteroid Nasacort AQ to OTC sale, to be indicated for relief of hay fever symptoms in adults and children.

Merck's Frazier Promoted To CEO To Drive Post-Schering Success

Merck & Co. announced Nov. 30 it promoted current president Kenneth Frazier to CEO effective Jan. 1.

Related Content

Topics

UsernamePublicRestriction

Register

PS103168

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel